Evidence map›Paper›PMID 30298063›Full record

ReviewFrontiers in immunology2018

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.

Dorian Stolk, Hans J van der Vliet, Tanja D de Gruijl, Yvette van Kooyk, Mark A Exley

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Enhanced development of functional human NK cells in NOD-scid-IL2rgFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. YY1Scientific reports · 2020
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Dorian StolkDepartment of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands.
Hans J van der VlietDepartment of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands.
Tanja D de GruijlDepartment of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands.
Yvette van KooykDepartment of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands.
Mark A ExleyFaculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Amsterdam UMC Location VUmc · NLAgenus (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immune cells are active at the front line of host defense against pathogens and now appear to play a range of roles under non-infectious conditions as well, most notably in cancer. Establishing the balance of innate immune responses is critical for the "flavor" of these responses and subsequent adaptive immunity and can be either "good or bad" in controlling cancer progression. The importance of innate NK cells in tumor immune responses has already been extensively studied over the last few decades, but more recently several relatively mono- or oligo-clonal [i.e., (semi-) invariant] innate T cell subsets received substantial interest in tumor immunology including invariant natural killer T (iNKT), γδ-T and mucosal associated invariant T (MAIT) cells. These subsets produce high levels of various pro- and/or anti-inflammatory cytokines/chemokines reflecting their capacity to suppress or stimulate immune responses. Survival of patients with cancer has been linked to the frequencies and activation status of NK, iNKT, and γδ-T cells. It has become clear that NK, iNKT, γδ-T as well as MAIT cells all have physiological roles in anti-tumor responses, which emphasize their possible relevance for tumor immunotherapy. A variety of clinical trials has focused on manipulating NK, iNKT, and γδ-T cell functions as a cancer immunotherapeutic approach demonstrating their safety and potential for achieving beneficial therapeutic effects, while the exploration of MAIT cell related therapies is still in its infancy. Current issues limiting the full therapeutic potential of these innate cell subsets appear to be related to defects and suppressive properties of these subsets that, with the right stimulus, might be reversed. In general, how innate lymphocytes are activated appears to control their subsequent abilities and consequent impact on adaptive immunity. Controlling these potent regulators and mediators of the immune system should enable their protective roles to dominate and their deleterious potential (in the specific context of cancer) to be mitigated.

Indexed as

AnimalsCarcinogenesisCytokinesDisease ProgressionHumansImmune ToleranceImmunity, InnateImmunotherapyInflammationLymphocyte ActivationMucosal-Associated Invariant T CellsNatural Killer T-CellsNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesCytokinesReceptors, Antigen, T-Cell, gamma-deltacancer immunotherapyCD1dgamma-delta T cellsiNKT cellsMAIT cellsNK cellsNKT

Identifiers

PMID30298063
PMCPMC6161645
OpenAlexW2891930358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.